Kesimpta

Ofatumumab, the active ingredient in Kesimpta, is a CD20-directed cytolytic monoclonal antibody presented as a solution for subcutaneous injection for subcutaneous use. It is indicated for the treatment of relapsing forms of multiple sclerosis, providing a disease‑modifying therapy for adult patients.

GNH USA supplies Kesimpta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability across global markets. The product is manufactured under strict regulatory standards to meet the needs of multiple sclerosis treatment programs.

Kesimpta is a CD20‑directed monoclonal antibody used in the management of multiple sclerosis.

Relapsing‑remitting multiple sclerosis: reduces annualized relapse rate and delays disability progression. Active secondary progressive multiple sclerosis: decreases risk of disability worsening. Overall multiple sclerosis disease modification: lowers MRI lesion activity and overall disease activity.

Common Side Effects: - Injection site reactions such as redness, swelling, or pain. - Upper respiratory tract infections including nasopharyngitis. - Headache. - Fatigue. - Mild gastrointestinal discomfort. - Transient lymphopenia.

Serious or Rare Side Effects: - Severe or opportunistic infections, including pneumonia. - Reactivation of hepatitis B virus. - Progressive multifocal leukoencephalopathy (PML). - Anaphylactic reactions. - Significant cytopenias (e.g., neutropenia, thrombocytopenia). - Potential malignancies such as lymphoma.

Before initiating therapy, evaluate infection risk and screen for hepatitis B. Monitor patients regularly for signs of infection and changes in blood counts. Assess immunization status and avoid live vaccines during treatment. Discuss potential risks with women who are pregnant, planning pregnancy, or breastfeeding. Review any history of severe allergic reactions to monoclonal antibodies.

Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Major Interactions (Avoid): - Concurrent use with other B‑cell depleting agents: may cause excessive immunosuppression. - Live vaccines: increased risk of vaccine‑derived infection. - Uncontrolled hepatitis B infection: risk of severe reactivation.

Moderate Interactions (Monitor Closely): - Immunosuppressants such as azathioprine or methotrexate: may heighten infection risk. - Systemic corticosteroids: may augment overall immunosuppressive effect. - Inactivated vaccines: possible reduced immunogenic response, monitor efficacy.